Alnylam Pharmaceuticals
Delaware corporation
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Source: Wikipedia · CC BY-SA 4.0
last observed
Activity Score
—
not enough monitored evidence
Hiring Momentum 30d
—
not enough monitored evidence
Product Velocity
—
not enough monitored evidence
AI Adoption
—
not enough monitored evidence
Corporate Change Index
—
not enough monitored evidence
12 active sensors·0 observations·0 historical changes·0 structured events
Compare Alnylam Pharmaceuticals with peers on activity, hiring, product velocity, AI adoption, locations and events.
Compare companies